

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.



May 15, 2026

## Consolidated Financial Results for the Nine Months Ended March 31, 2026 (Under Japanese GAAP)

Company name: Asahi Intecc Co., Ltd.  
 Listing: Tokyo Stock Exchange and Nagoya Stock Exchange  
 Securities code: 7747  
 URL: <https://www.asahi-intecc.co.jp/>  
 Representative: Kenji Miyata, President & CEO  
 Inquiries: Mizuho Ito, Member of Board & CFO, General Manager of Administration  
 Telephone: +81-561-56-1851  
 Scheduled date of commencing dividend payments: –  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the nine months ended March 31, 2026 (from July 1, 2025 to March 31, 2026)

#### (1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended								
March 31, 2026	108,366	18.0	37,414	45.5	37,207	45.4	26,657	204.2
March 31, 2025	91,815	13.7	25,715	30.8	25,594	30.4	8,763	-37.6

Note: Comprehensive income For the nine months ended March 31, 2026: ¥32,866 million (490.8%)  
 For the nine months ended March 31, 2025: ¥5,563 million (-66.4%)

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
March 31, 2026	100.13	–
March 31, 2025	32.26	–

#### (2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Million yen	Million yen	%
March 31, 2026	203,730	167,159	81.6
June 30, 2025	193,187	151,354	77.9

Reference: Equity  
 As of March 31, 2026: ¥166,226 million  
 As of June 30, 2025: ¥150,558 million

## 2. Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
Fiscal year ended June 30, 2025	Yen —	Yen 0.00	Yen —	Yen 24.23	Yen 24.23
Fiscal year ending June 30, 2026	—	0.00	—		
Fiscal year ending June 30, 2026 (Forecast)				46.10	46.10

Note: Revisions to dividend forecasts announced most recently: None

## 3. Consolidated financial results forecast for the fiscal year ending June 30, 2026 (July 1, 2025 to June 30, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	141,142	17.6	42,220	40.4	42,688	44.4	30,556	139.9	114.88

Note: Revisions to financial results forecast announced most recently: None

\* **Notes**

(1) Significant changes in scope of consolidation during the period: None

Newly included: -

Excluded: -

(2) Accounting treatments adopted specially for the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	265,332,300 shares
As of June 30, 2025	271,633,600 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	7,977 shares
As of June 30, 2025	1,964,677 shares

(iii) Average number of shares during the period (cumulative)

Nine months ended March 31, 2026	266,219,637 shares
Nine months ended March 31, 2025	271,625,628 shares

\* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

\* Proper use of earnings forecasts, and other special matters

Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to “1. Qualitative information on results for the quarter under review (3) Explanation of forecasts including consolidated results forecast” on page 3 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

## Table of contents of the attached materials

1. Qualitative information on results for the quarter under review .....	2
(1) Explanation of operating results .....	2
(2) Explanation of financial position .....	3
(3) Explanation of forecasts including consolidated results forecast .....	3
2. Quarterly consolidated financial statements and major notes .....	4
(1) Quarterly consolidated balance sheet.....	4
(2) Quarterly consolidated statements of income and comprehensive income .....	6
(3) Notes to quarterly consolidated financial statements .....	8
(Note on entity's ability to continue as going concern).....	8
(Notes on change in scope of consolidation or scope of application of equity method).....	8
(Notes in the case of significant changes in amount of shareholders' equity).....	8
(Segment Information, etc.) .....	9
(Note to statement of cash flows).....	10
(Revenue recognition).....	10
(Significant subsequent events).....	11

## 1. Qualitative information on results for the quarter under review

### (1) Explanation of operating results

The Asahi Intecc Group (the Group) aims to maintain a high level of growth and further enhance its corporate value by steadily promoting the growth strategies set forth in its new medium-term management plan, “Building the Future 2030,” which begins in the fiscal year ending June 30, 2026.

The Group’s performance for the nine months ended March 31, 2026 progressed favorably, as follows.

Net sales amounted to 108,366 million yen (an increase of 18.0% year on year), driven by the strong performance of both the Medical and Device Divisions.

Gross profit totaled 76,788 million yen (an increase of 23.3% year on year), due to the increase in net sales and improvement in the gross profit margin in line with productivity improvements.

Operating profit was 37,414 million yen (an increase of 45.5% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the U.S., as well as an increase in R&D expenses.

Ordinary profit was 37,207 million yen (an increase of 45.4% year on year), due to a decrease in subsidy income and a decrease in foreign exchange losses.

Profit attributable to owners of parent was 26,657 million yen (an increase of 204.2% year on year), due to a significant decrease in impairment losses.

Foreign exchange rates used for the nine months ended March 31, 2026:

152.73 yen per U.S. dollar (151.48 yen for the same period of the previous fiscal year, up 0.8%)

178.34 yen per euro (162.50 yen for the same period of the previous fiscal year, up 9.7%)

21.64 yen per Chinese yuan (20.98 yen for the same period of the previous fiscal year, up 3.1%)

4.77 yen per Thai baht (4.42 yen for the same period of the previous fiscal year, up 7.9%)

The operating results for each segment are outlined below.

#### <Medical Division>

In the Medical Division, net sales increased in all regions, both in Japan and overseas.

In the domestic market, net sales increased mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields. In the cardiovascular field, net sales increased primarily for PCI guide wires and penetration catheters in all regions. In the non-cardiovascular field, net sales increased due to strong sales of peripheral vascular and abdominal products in all regions.

As a result, net sales totaled 94,766 million yen (an increase of 14.6% year on year).

Segment profit amounted to 36,132 million yen (an increase of 31.8% year on year).

#### <Device Division>

In the Device Division, net sales increased in both medical and industrial components.

In addition, from the current fiscal year, Nitta Mold was included in the scope of consolidation as a consolidated subsidiary, and the company’s profit and loss were reflected in the Group’s consolidated results.

As for medical components, net sales increased mainly due to an increase in transactions in cardiovascular inspection catheter components for U.S. companies and transactions in cardiovascular ultrasound catheter components for Asia, as well as the consolidation of Nitta Mold as a subsidiary.

As for industrial components, net sales increased mainly due to an increase in leisure-related transactions in the overseas market and the consolidation of Nitta Mold as a subsidiary.

As a result, net sales totaled 13,600 million yen (an increase of 49.5% year on year).

Segment profit amounted to 7,274 million yen (an increase of 88.6% year on year), mainly due to an increase in revenues from external customers.

(2) Explanation of financial position

As of March 31, 2026, total assets amounted to 203,730 million yen, an increase of 10,542 million yen from the end of the previous fiscal year. This was mainly due to increases of 5,596 million yen in cash and deposits, 3,417 million yen in notes and accounts receivable - trade, and 1,012 million yen in raw materials and supplies.

As for liabilities, total liabilities amounted to 36,570 million yen, a decrease of 5,262 million yen from the end of the previous fiscal year. This was mainly due to decreases of 1,772 million yen in long-term borrowings and 1,249 million yen in provision for bonuses.

As for net assets, total net assets amounted to 167,159 million yen, an increase of 15,805 million yen from the end of the previous fiscal year. This was mainly due to increases of 8,069 million yen in retained earnings and 6,476 million yen in foreign currency translation adjustment.

(3) Explanation of forecasts including consolidated results forecast

There are no changes to the consolidated financial results forecast for the fiscal year ending June 30, 2026, from the content of the “Notice Regarding Revision (Upward Revision) of Full-Year Consolidated Financial Results Forecast for the Fiscal Year Ending June 30, 2026” announced on February 13, 2026.

If revisions to the financial results forecast become necessary in the future, the Company will promptly announce them.

Note: Financial results forecasts and other forward-looking statements are based on certain assumptions that the Group deems reasonable in light of information currently available, including economic conditions in Japan and overseas, fluctuations in foreign exchange rates, and other factors that may affect financial results, and do not represent any guarantee that the Company will achieve these results. They are affected by many uncertain factors, including market conditions, competitive conditions, and the introduction and success or failure of new products. Therefore, please note that actual net sales and profits may differ significantly from the forecast figures stated.

## 2. Quarterly consolidated financial statements and major notes

### (1) Quarterly consolidated balance sheet

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Nine months under review (March 31, 2026)
<b>Assets</b>		
Current assets		
Cash and deposits	54,200	59,797
Notes and accounts receivable - trade	15,767	19,184
Electronically recorded monetary claims - operating	2,026	2,061
Merchandise and finished goods	9,408	9,581
Work in process	8,785	9,690
Raw materials and supplies	6,458	7,470
Other	7,004	7,067
Allowance for doubtful accounts	-291	-310
<b>Total current assets</b>	<b>103,359</b>	<b>114,543</b>
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	32,523	34,778
Other, net	26,559	25,456
<b>Total property, plant and equipment</b>	<b>59,082</b>	<b>60,235</b>
Intangible assets		
Goodwill	110	29
Other	5,485	5,128
<b>Total intangible assets</b>	<b>5,595</b>	<b>5,158</b>
Investments and other assets		
Investment securities	19,389	18,529
Other	5,760	5,263
<b>Total investments and other assets</b>	<b>25,149</b>	<b>23,793</b>
<b>Total non-current assets</b>	<b>89,827</b>	<b>89,186</b>
<b>Total assets</b>	<b>193,187</b>	<b>203,730</b>

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Nine months under review (March 31, 2026)
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable – trade	2,655	3,381
Electronically recorded obligations - operating	424	727
Short-term borrowings	2,387	2,367
Income taxes payable	4,789	5,320
Provision for bonuses	2,868	1,619
Other	14,730	9,315
<b>Total current liabilities</b>	<b>27,856</b>	<b>22,732</b>
Non-current liabilities		
Long-term borrowings	6,633	4,861
Provision for retirement benefits for directors (and other officers)	19	19
Retirement benefit liability	2,943	3,360
Asset retirement obligations	197	200
Other	4,182	5,396
<b>Total non-current liabilities</b>	<b>13,976</b>	<b>13,838</b>
<b>Total liabilities</b>	<b>41,833</b>	<b>36,570</b>
Net assets		
Shareholders' equity		
Share capital	18,860	18,860
Capital surplus	21,779	18,872
Retained earnings	97,947	106,016
Treasury shares	-4,453	-18
<b>Total shareholders' equity</b>	<b>134,134</b>	<b>143,730</b>
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,008	1,657
Foreign currency translation adjustment	14,315	20,792
Remeasurements of defined benefit plans	99	45
<b>Total accumulated other comprehensive income</b>	<b>16,424</b>	<b>22,495</b>
Non-controlling interests	795	932
<b>Total net assets</b>	<b>151,354</b>	<b>167,159</b>
<b>Total liabilities and net assets</b>	<b>193,187</b>	<b>203,730</b>

## (2) Quarterly consolidated statements of income and comprehensive income

## Quarterly consolidated statement of income

For the nine months ended March 31

(Million yen)

	Previous nine months period (from July 1, 2024 to March 31, 2025)	Nine months under review (from July 1, 2025 to March 31, 2026)
Net sales	91,815	108,366
Cost of sales	29,551	31,578
Gross profit	62,263	76,788
Selling, general and administrative expenses	36,548	39,374
Operating profit	25,715	37,414
Non-operating income		
Interest income	81	148
Dividend income	85	48
Subsidy income	864	175
Other	206	156
Total non-operating income	1,236	529
Non-operating expenses		
Interest expenses	204	99
Foreign exchange losses	948	369
Other	204	266
Total non-operating expenses	1,357	735
Ordinary profit	25,594	37,207
Extraordinary income		
Gain on sale of investment securities	23	1,527
Reversal of allowance for doubtful accounts	100	–
Total extraordinary income	123	1,527
Extraordinary losses		
Impairment losses	9,300	–
Loss on valuation of investment securities	759	156
Loss on sale of investment securities	–	6
Loss on valuation of shares of subsidiaries and associates	210	784
Provision of allowance for doubtful accounts for subsidiaries and associates	461	–
Total extraordinary losses	10,730	946
Profit before income taxes	14,987	37,788
Income taxes - current	6,953	9,421
Income taxes - deferred	-780	1,642
Total income taxes	6,172	11,064
Profit	8,815	26,724
Profit attributable to non-controlling interests	52	67
Profit attributable to owners of parent	8,763	26,657

Quarterly consolidated statement of comprehensive income  
For the nine months ended March 31

(Million yen)

	Previous nine months period (from July 1, 2024 to March 31, 2025)	Nine months under review (from July 1, 2025 to March 31, 2026)
Profit	8,815	26,724
Other comprehensive income		
Valuation difference on available-for-sale securities	-469	-351
Foreign currency translation adjustment	-2,764	6,546
Remeasurements of defined benefit plans, net of tax	-18	-53
Total other comprehensive income	-3,252	6,141
Comprehensive income	5,563	32,866
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	5,519	32,729
Comprehensive income attributable to non-controlling interests	43	137

(3) Notes to quarterly consolidated financial statements

(Note on entity's ability to continue as going concern)

Not applicable.

(Notes on change in scope of consolidation or scope of application of equity method)

During the three months ended September 30, 2025, Nitta Mold Co., Ltd. and its subsidiary, NITTA M&T (THAILAND) CO., LTD., were included in the scope of consolidation.

(Notes in the case of significant changes in amount of shareholders' equity)

(Purchase of treasury shares)

Based on the resolution of the Board of Directors' meeting held on May 15, 2025, the Company acquired 4,344,600 shares of treasury shares during the nine months ended March 31, 2026. As a result, treasury shares increased by 10,553 million yen.

(Cancellation of treasury shares)

Based on the resolution of the Board of Directors' meeting held on May 15, 2025, the Company cancelled 6,301,300 shares of treasury shares during the nine months ended March 31, 2026 pursuant to Article 178 of the Companies Act.

As a result, capital surplus decreased by 2,907 million yen, retained earnings decreased by 12,080 million yen, and treasury shares decreased by 14,988 million yen. Capital surplus amounted to 18,872 million yen, retained earnings amounted to 106,016 million yen, and treasury shares amounted to 18 million yen as of March 31, 2026.

(Segment Information, etc.)

[Segment Information]

I Nine months ended March 31, 2025 (from July 1, 2024 to March 31, 2025)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	82,721	9,094	91,815	–	91,815
Transactions with other segments	–	10,787	10,787	-10,787	–
Total	82,721	19,881	102,602	-10,787	91,815
Segment profit	27,416	3,856	31,273	-5,557	25,715

- Notes: 1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
2. Segment profit is adjusted with the operating profit in the quarterly consolidated statement of income.

II Nine months ended March 31, 2026 (from July 1, 2025 to March 31, 2026)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	94,766	13,600	108,366	–	108,366
Transactions with other segments	–	12,652	12,652	-12,652	–
Total	94,766	26,253	121,019	-12,652	108,366
Segment profit	36,132	7,274	43,407	-5,993	37,414

- Notes: 1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
2. Segment profit is adjusted with the operating profit in the quarterly consolidated statement of income.

(Note to statement of cash flows)

The quarterly consolidated statement of cash flows for the nine months ended March 31, 2026 has not been prepared.

Depreciation (including amortization of intangible assets excluding goodwill) and amortization of goodwill

	Previous nine months period (from July 1, 2024 to March 31, 2025)	Nine months under review (from July 1, 2025 to March 31, 2026)
Depreciation	7,058 million yen	6,618 million yen
Amortization of goodwill	934 million yen	87 million yen

(Revenue recognition)

Disaggregation of revenue from contracts with customers

(1) Breakdown by type

Nine months ended March 31, 2025 (from July 1, 2024 to March 31, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	62,649	–	62,649
Non-cardiovascular	14,174	–	14,174
OEM	5,897	–	5,897
Medical Components	–	6,019	6,019
Industrial Components	–	3,074	3,074
Total	82,721	9,094	91,815

Nine months ended March 31, 2026 (from July 1, 2025 to March 31, 2026)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	71,337	–	71,337
Non-cardiovascular	17,673	–	17,673
OEM	5,754	–	5,754
Medical Components	–	8,651	8,651
Industrial Components	–	4,948	4,948
Total	94,766	13,600	108,366

(2) Breakdown by region

Nine months ended March 31, 2025 (from July 1, 2024 to March 31, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	11,967	2,084	14,052
North America	17,033	2,874	19,907
Europe	18,071	376	18,448
China	23,101	405	23,506
Others	12,547	3,353	15,900
Total	82,721	9,094	91,815

Nine months ended March 31, 2026 (from July 1, 2025 to March 31, 2026)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	12,594	2,801	15,395
North America	19,181	4,751	23,933
Europe	21,346	413	21,760
China	28,092	457	28,549
Others	13,551	5,175	18,727
Total	94,766	13,600	108,366

(Significant subsequent events)

Not applicable.